Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy

#2121

Introduction: Neuroendocrine carcinomas (NEC) (high grade Ki67 > 20%) were poor prognostic and lethal disease. Platinum-based chemotherapy is usually chosen as a first line treatment for advanced NEC, however, this efficacy is temporary and there is no standard second-line treatment yet. Temozolomide is a good candidate, however it was not approved for NEC by Japanese authorities.

Aim(s): The aim of this study is the efficacy and safety of temozolomide monotherapy for advanced NEC patients with resistant to platinum-based chemotherapy.

Materials and methods: The dose of temozolomide was 200mg/m2 from day1 to 5 every 4 weeks. This study was designed as prospective Phase II. Primary end point was response rate (RR) and secondary end point was disease control rate (DCR), progression free survival (PFS), overall survival (OS) and safety.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ichikawa Y, Kobayashi N, Tokuhisa M, Goto A, Hiroshima Y,

Keywords: Neuroendocrine Carcinoma, Temozolomide,

To read the full abstract, please log into your ENETS Member account.